Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Antiviral Res. 2016 Apr 6;131:19–25. doi: 10.1016/j.antiviral.2016.03.015

Table 3.

Preliminary mechanism of action studies suggest that compounds from Series 1 target the RSV polymerase. Activity of select compounds against RSV strains containing mutations rendering them resistant to inhibitors of the viral polymerase (L protein, Sudo et al., 2005) or the nucleocapsid protein (N, Chapman et al., 2007) was assessed in CPE assays. Compounds from Series 1 showed a shift in activity against the L mutant virus but no significant shift in activity against the N mutant virus.

BRD9101 BRD3969 BRD65768
RSV A2 EC50 1.7 μM 3.9 μM 6.1 μM
N Mutant (fold shift) 7.8 μM (4.6x) 6.9 μM (1.8x) 13.1 μM (2x)
L Mutant (fold shift) > 25 μM (>19x) > 25 μM (>6x) > 25 μM (>4x)